Jill Feldman, Lung Cancer Patient and Advocate, shared an update from EGFR Resisters Research Summit, on X, adding:
“One of my favorite of all the advocacy work I do. Bringing early-career investigators together with mentors, peers, and patient advocates, and getting to see their ideas, passion, and commitment to advancing EGFR research firsthand. The future of lung cancer is bright, and these young investigators are a big reason why.”
Quoting EGFR Resisters Research Summit:
“We’re officially one month away from the 2026 EGFR Resisters Research Summit! Young Investigators working to advance research in EGFR-mutated NSCLC will come together in Chicago for two days of research presentations, expert mentorship, career development, and meaningful collaboration with peers and patient advocates.
November 5–6, 2026
Hyatt Centric Chicago O’Hare.”
This also can be interesting:
KEYNOTE-671: Perioperative Pembrolizumab Redefines Curative-Intent Therapy in Resectable NSCLC
